Alphamab Oncology Reports Full Year 2023 Financial Results a

SUZHOU, China, March 29, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) reported financial results for the full year ended December 31, 2023 and

Related Keywords

Australia , Hong Kong , Russia , India , United States , Suzhou , Jiangsu , China , Thailand , Singapore , Malaysia , America , Australian , American , Chinese , Jiangsu Alphamab , Asia Pacific , Pharmaceuticals Inc , Chinese Pharmaceutical Innovative Enterprises , China National Medical Products Administration , Hong Kong Stock Exchange , Drug Administration , Bellberry Human Research Ethics Committee , Society For Immunotherapy Of Cancer , Chinese Pharmaceutical Listed Companies , European Society For Medical Oncology Congress , Nature Communications , American Association For Cancer Research , Alphamab Oncology , European Journal , Medical Oncology Congress , Cell Reports Medicine , Drug Evaluation , San Antonio Breast Cancer Symposium , Cancer Research , United States Food , Middle East , Independent States , Bellberry Human Research Ethics , Stemirna Therapeutics , Late Breaking Research , Pharmaceutical Innovative , Pharmaceutical Listed Companies , Healthcare Executive , Main Board , Breakthrough Designation , China National Medical Products , Thailand Business ,